Dr. Lan’s presentation introduces 2 innovative approaches – the K-TRACK and K-4CARE test - two tumor-informed assays that uniquely combine tissue and liquid biopsy into a single, cost-efficient workflow, achieving limit of detection (LOD) down to 0.01%. Beyond DNA- based actionable mutations, these assays cover RNA-based fusions, MSI, TMB, germline mutations, viral DNA, and ctDNA-MRD—backed by both prospective trials and real-world data. With real-time monitoring, transcriptomic profiling, and AI-powered origin prediction, these solutions are designed to optimize treatment pathways from early- stage to metastatic disease
